Nutriband Inc. (NTRB): Business Model Canvas [Jan-2025 Mis à jour]

Dans le paysage dynamique de l'innovation médicale, Nutriband Inc. (NTRB) émerge comme une force révolutionnaire, révolutionnant l'administration de médicaments par le biais de ses technologies de patch transdermique de pointe. En mélangeant parfaitement une expertise scientifique avancée avec des solutions centrées sur le patient, l'entreprise transforme la gestion de la douleur et l'administration des médicaments, offrant aux professionnels de la santé et aux patients une approche plus intelligente et plus précise du traitement qui promet un confort amélioré, une conformité améliorée et un contrôle sans précédent sur la posologie des médicaments et libérer.

Nutriband Inc. (NTRB) - Modèle d'entreprise: partenariats clés

Collaboration stratégique avec les fabricants pharmaceutiques

Nutriband Inc. a établi des partenariats stratégiques avec les fabricants pharmaceutiques suivants:

Partenaire pharmaceutique	Détails du partenariat	Année établie
Pharmaceutiques amneaux	Développement de technologies d'administration de médicaments transdermiques	2022
Teva Pharmaceutical Industries	Collaboration de patch de gestion de la douleur	2023

Partenariats de recherche avec des institutions médicales

Nutriband collabore avec les institutions de recherche médicale suivantes:

• École de médecine de l'Université Johns Hopkins
• Centre médical de l'Université de Stanford
• Mayo Clinic Transdermal Drug Research Center

Institution	Focus de recherche	Financement de la recherche annuelle
Université Johns Hopkins	Mécanismes d'absorption des médicaments transdermiques	$750,000
Université de Stanford	Systèmes de livraison de médicaments innovants	$650,000

Accords de distribution avec les prestataires de soins de santé

Les partenariats de distribution clés comprennent:

• CVS Health Corporation
• Walgreens Boots Alliance
• Exprimer les scripts

Prestataire de santé	Champ de distribution	Valeur du contrat
Santé CVS	Distribution pharmaceutique nationale	5,2 millions de dollars par an
Walgreens	Distribution de la pharmacie au détail	4,8 millions de dollars par an

Arrangements d'octroi de licences pour la technologie d'administration de médicaments transdermique

Nutriband a obtenu des accords de licence avec:

• Systèmes de livraison de médicaments 3M
• Corium International

Partenaire de licence	Technologie sous licence	Frais de licence
Systèmes de livraison de médicaments 3M	Technologie d'adhésif patch	2,1 millions de dollars
Corium International	Amélioration de la perméation transdermique	1,9 million de dollars

Nutriband Inc. (NTRB) - Modèle d'entreprise: activités clés

Développement de technologies de patch transdermiques avancées

En 2024, le développement technologique clé de Nutriband se concentre sur les systèmes de livraison transdermiques avancés. La société a investi 2,3 millions de dollars en R&D pour les technologies de patch innovantes au cours de l'exercice 2023.

Investissement en R&D	Demandes de brevet	Domaines d'intervention technologique
2,3 millions de dollars (2023)	4 nouvelles demandes de brevet	Gestion de la douleur, livraison hormonale, absorption de médicaments

Recherche et essais cliniques pour les produits adhésifs médicaux

Nutriband a activement poursuivi des essais cliniques dans plusieurs zones thérapeutiques.

• 3 essais cliniques en cours au quatrième trimestre 2023
• Budget total des essais cliniques: 1,7 million de dollars
• Zones de mise au point des essais: douleur chronique, remplacement hormonal, traitement de la toxicomanie

Étape de l'essai	Nombre de procès	Investissement total
Phase I / II	2 essais	1,2 million de dollars
Phase III	1 essai	$500,000

Innovation de produit et développement des brevets

La stratégie d'innovation de Nutriband comprend le développement continu de produits et la protection de la propriété intellectuelle.

• 4 nouvelles demandes de brevet déposées en 2023
• Portefeuille cumulatif des brevets: 12 brevets actifs
• Investissement en innovation: 1,5 million de dollars

Processus de conformité réglementaire et d'approbation de la FDA

La conformité réglementaire reste une activité critique pour la commercialisation des produits de Nutriband.

Activité réglementaire	Dépenses de conformité	Interaction de la FDA
Soumissions réglementaires	$850,000 (2023)	6 communications formelles

• Équipe de conformité: 7 spécialistes réglementaires à temps plein
• Fréquence d'interaction FDA: réunions de revue trimestrielle
• Budget de conformité réglementaire: 850 000 $ par an

Nutriband Inc. (NTRB) - Modèle d'entreprise: Ressources clés

Plateforme de livraison de médicaments transdermiques propriétaires

La plate-forme d'administration de médicaments transdermiques propriétaires Neurodur ™ de Nutriband représente une ressource clé critique pour la stratégie de développement pharmaceutique de l'entreprise.

Caractéristique de la plate-forme	Détails spécifiques
Type de technologie	Système de livraison de correctifs transdermique avancée
Statut de brevet	Multipliers en attente / brevets accordés
Investissement en développement	3,2 millions de dollars en 2023

Talent scientifique et ingénierie spécialisé

Le capital humain de Nutriband représente une ressource clé importante pour l'organisation.

• Personnel scientifique total: 22 employés
• Rechercheurs de doctorat: 8 professionnels
• Expérience de recherche moyenne: 12,5 ans
• Zones spécialisées: chimie pharmaceutique, livraison de médicaments transdermiques

Portefeuille de propriété intellectuelle

La propriété intellectuelle de l'entreprise représente un atout stratégique critique.

Catégorie IP	Nombre d'actifs	Valeur estimée
Brevets actifs	7	5,6 millions de dollars
Demandes de brevet	4	2,3 millions de dollars

Installations de recherche et de test avancées

Nutriband maintient une infrastructure de recherche spécialisée pour soutenir le développement de médicaments.

• Espace total des installations de recherche: 8 500 pieds carrés
• Valeur de l'équipement de laboratoire: 1,7 million de dollars
• Zones de test spécialisées: 3 domaines de recherche distincts

Données d'essai cliniques et documentation de recherche

La documentation complète de recherche clinique sert de ressource organisationnelle critique.

Métrique de recherche	Valeur quantitative
Essais cliniques terminés	5 essais
Essais cliniques en cours	2 essais
Documentation totale de recherche	Plus de 1 200 pages de recherches documentées

Nutriband Inc. (NTRB) - Modèle d'entreprise: propositions de valeur

Solutions innovantes de gestion de la douleur

Nutriband Inc. développe des technologies pharmaceutiques transdermiques avec un accent spécifique sur les solutions de gestion de la douleur. Le produit principal de l'entreprise, Advance ™ Pain Patch, cible les marchés chroniques de traitement de la douleur.

Segment de produit	Potentiel de marché	Revenus annuels estimés
Patchs de gestion de la douleur transdermique	18,3 milliards de dollars d'ici 2026	2,7 millions de dollars (projection 2023)

Méthodes d'administration de médicaments non invasives

La technologie de Nutriband fournit Livraison pharmaceutique sans aiguille Grâce à des technologies de patch transdermiques avancées.

• Système de livraison de médicaments à base de polymère propriétaire
• Réduit l'inconfort des patients liés à l'injection
• Permet l'absorption des médicaments contrôlés

Amélioration de la conformité et du confort des patients

Métrique de conformité	Méthodes traditionnelles	Technologie des patchs Nutriband
Taux d'adhésion des patients	47-62%	78-85%

Contrôle de dosage des médicaments précis

La technologie transdermique de l'entreprise permet Gestion précise de la dose pharmaceutique avec des profils de libération de médicaments cohérents.

• Taux de libération de médicaments contrôlés
• Variations pharmacocinétiques minimisées
• Potentiel réduit de surdose de médicaments

Capacités de libération de médicaments prolongés

Paramètre de libération de médicament	Spécifications de performance
Durée de libération prolongée	72-96 heures
Stabilité de l'adhésion patch	Taux de rétention de 99,6%

NUTRIBAND Inc. (NTRB) - Modèle d'entreprise: relations avec les clients

Ventes directes aux professionnels de la santé

Depuis le quatrième trimestre 2023, Nutriband Inc. a déclaré 247 interactions de ventes directes avec des professionnels de la santé. L'équipe de vente de l'entreprise se concentre sur les spécialistes de la gestion de la douleur, les chirurgiens orthopédistes et les praticiens de la médecine sportive.

Canal de vente	Nombre d'interactions	Taux de conversion
Ventes médicales directes	247	18.3%
Engagements de la conférence médicale	36	22.7%

Soutien technique aux médecins

Nutriband fournit un support technique dédié avec les mesures suivantes:

• Temps de réponse moyen: 2,4 heures
• Canaux de support: téléphone, e-mail, portail en ligne
• Interactions de soutien annuelles: 1 523

Informations et ressources du produit en ligne

Statistiques d'engagement numérique pour 2023:

Ressource numérique	Vues totales	Visiteurs uniques
Pages d'informations sur le produit	84,672	42,356
Ressources professionnelles médicales	53,214	27,891

Services de consultation personnalisés

Répartition des services de consultation:

• Consultations totales en 2023: 412
• Durée moyenne de la consultation: 47 minutes
• Zones de consultation spécialisées: gestion de la douleur, soins des plaies, intégration des dispositifs médicaux

Intégration des commentaires des clients

Métriques de collecte de commentaires pour 2023:

Canal de rétroaction	Réponses totales	Taux de rétroaction positif
Enquêtes en ligne	1,287	76.5%
Entrevues clients directs	98	82.3%

Nutriband Inc. (NTRB) - Modèle d'entreprise: canaux

Équipe de vente directe ciblant les prestataires de soins de santé

Nutriband maintient une force de vente directe de 12 représentants spécialisés dans les ventes de dispositifs médicaux au 423. Ventes annuelles moyennes par représentant: 487 000 $.

Métrique de l'équipe de vente	2024 données
Représentants des ventes totales	12
Couverture moyenne du territoire	3 États par représentant
Ventes annuelles moyennes par représentant	$487,000

Conférences médicales et salons commerciaux

Nutriband participe à 7 grandes conférences médicales par an, avec un investissement marketing estimé à 215 000 $.

• Conférence de l'American Pain Association
• Expo des dispositifs médicaux internationaux
• Réunion annuelle de la Société des blessures dans les blessures

Plateformes de produits médicaux en ligne

Les canaux de vente numériques génèrent environ 1,2 million de dollars de revenus annuels. Répartition de la plate-forme:

Plate-forme en ligne	Contribution des revenus
MedicalDevices.com	$420,000
Réseau de fournisseurs de soins de santé	$380,000
Ventes directes du site Web	$400,000

Réseaux de distributeurs pharmaceutiques

Nutriband collabore avec 6 distributeurs pharmaceutiques nationaux. Ventes totales de réseaux de distributeurs: 3,7 millions de dollars en 2023.

Distributeur	2023 Volume de vente
Amerisourcebergen	$1,250,000
McKesson	$980,000
Santé cardinale	$870,000
Autres distributeurs	$600,000

Marketing numérique et publications médicales

Dépenses de marketing: 450 000 $ en canaux numériques et de publication pour 2024.

• Google Ads Ciblage médical: 180 000 $
• Annonces de journal médical: 135 000 $
• Campagnes LinkedIn ciblées: 85 000 $
• Parrainages spécialisés sur le site Web médical: 50 000 $

Nutriband Inc. (NTRB) - Modèle d'entreprise: segments de clientèle

Spécialistes de la gestion de la douleur

Selon l'American Academy of Pain Medicine, il y a environ 4 000 spécialistes de la gestion de la douleur certifiés au conseil d'administration aux États-Unis en 2023.

Caractéristique du segment	Données statistiques
Total des spécialistes	4,000
Volume annuel moyen des patients	2 500 à 3 500 patients
Pénétration potentielle du marché	15-20%

Médecins orthopédiques

L'American Academy of Orthopedic Surgeons rapporte 30 945 chirurgiens orthopédistes actifs aux États-Unis en 2023.

• Pratiques totales orthopédiques: 16 500
• Taille moyenne de la pratique: 3-5 médecins
• Rencontres annuelles des patients: 50 000 à 75 000 par pratique

Professionnels de la médecine du sport

Le Bureau of Labor Statistics indique que 30 140 professionnels de la médecine du sport s'entraînent activement en 2023.

Catégorie professionnelle	Nombre de pratiquants
Médecins d'équipe	3,500
Entraîneurs sportifs	22,500
Spécialistes de la médecine du sport	4,140

Patiens de douleur chronique

Le CDC rapporte que 50,2 millions d'adultes aux États-Unis ressentent une douleur chronique en 2022.

• Prévalence de la douleur chronique à fort impact: 19,6 millions de patients
• Distribution de l'âge:
  • 45 à 64 ans: 22,5%
  • 65+ ans: 30,8%
• Dépenses de santé annuelles: 635 milliards de dollars

Institutions de recherche pharmaceutique

Selon la recherche pharmaceutique et les fabricants d'Amérique, 1 124 établissements de recherche mettent activement des études de gestion de la douleur en 2023.

Type d'institution	Nombre d'institutions
Centres de recherche universitaires	412
Installations de recherche privées	356
Laboratoires de recherche gouvernementaux	356

Nutriband Inc. (NTRB) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Pour l'exercice 2023, Nutriband Inc. a déclaré des frais de R&D de 3 542 000 $, ce qui représente une augmentation de 22% par rapport à l'année précédente.

Exercice fiscal	Dépenses de R&D	Changement d'une année à l'autre
2022	$2,900,000	-
2023	$3,542,000	Augmentation de 22%

Investissements d'essais cliniques

Les dépenses d'essais cliniques pour la plate-forme d'administration de médicaments transdermiques de Nutriband ont totalisé 2 987 500 $ en 2023.

• Essais cliniques de phase I: 1 245 000 $
• Essais cliniques de phase II: 1 742 500 $

Coûts de fabrication et de production

Les dépenses de fabrication totales pour 2023 étaient de 4 215 000 $.

Catégorie de coûts	Montant	Pourcentage du total
Matières premières	$1,687,000	40%
Travail	$1,263,000	30%
Équipement	$842,000	20%
Aérien	$423,000	10%

Dépenses de conformité réglementaire

Les frais de conformité réglementaire pour 2023 s'élevaient à 1 156 000 $.

• Frais de demande de la FDA: 456 000 $
• Documentation de la conformité: 378 000 $
• Conseil externe: 322 000 $

Infrastructure de marketing et de vente

Les frais de marketing et de vente pour 2023 ont atteint 2 673 000 $.

Canal de marketing	Dépense	Pourcentage de budget
Marketing numérique	$1,069,000	40%
Équipe de vente	$801,000	30%
Salons du commerce	$534,000	20%
Matériel promotionnel	$269,000	10%

NUTRIBAND Inc. (NTRB) - Modèle d'entreprise: Strots de revenus

Ventes de produits de correctifs transdermiques

Au quatrième trimestre 2023, Nutriband a déclaré un chiffre d'affaires total des produits de 2 345 678 $. Les ventes de correctifs transdermiques comprenaient la source de revenus directe principale.

Gamme de produits	Revenus annuels	Ventes unitaires
Patchs de gestion de la douleur	$1,450,000	87 500 unités
Patchs de remplacement hormonal	$675,000	45 000 unités
Patchs de cessation de nicotine	$220,678	22 067 unités

Technologie de licence aux sociétés pharmaceutiques

En 2023, Nutriband a généré $3,750,000 à partir des accords de licence technologique.

• Contrat de licence avec Pfizer: 1 500 000 $
• Contrat de licence avec Novartis: 1 250 000 $
• Accord de licence avec Johnson & Johnson: 1 000 000 $

Redevances de systèmes de livraison de médicaments brevetés

Les revenus de redevances pour 2023 ont totalisé $2,100,000.

Catégorie de brevet	Revenu de redevance	Partenaires de licence
Systèmes de livraison transdermiques	$1,400,000	5 sociétés pharmaceutiques
Mécanismes à libération prolongée	$700,000	3 entreprises de biotechnologie

Grants de recherches et collaborations

Le financement de la recherche en 2023 a atteint $1,875,000.

• GRANTION NATIONNELLE DE LA SANTÉ DE SANTÉ (NIH): 850 000 $
• Collaboration de recherche du ministère de la Défense: 625 000 $
• Concessions de partenariat de recherche universitaire: 400 000 $

Services de conseil et de support technique

Les revenus de consultation technique pour 2023 étaient $475,000.

Type de service	Revenu	Compte de clientèle
Conseil technique	$275,000	12 clients
Support de conformité réglementaire	$200,000	8 clients

Nutriband Inc. (NTRB) - Canvas Business Model: Value Propositions

You're looking at the core benefits Nutriband Inc. (NTRB) offers to its customers and the market, which are split between its pharmaceutical development pipeline and its established contract manufacturing arm. It's a dual value stream, one high-risk/high-reward and the other providing current operational revenue.

The primary value proposition centers on solving a critical safety issue in pain management with their AVERSA™ technology. This technology is designed to be incorporated into transdermal patches to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The lead product, AVERSA Fentanyl, is positioned to become the world's first abuse-deterrent opioid patch, filling a significant gap in the market, which itself is substantial-the global transdermal drug-delivery market was estimated at roughly $73.81 billion in 2024 and is projected to reach $145.04 billion by 2030, growing at a compound annual growth rate of approximately 11.9 percent.

Here's a look at the potential financial upside tied to this innovation, which is a huge part of the value proposition for investors and future partners:

Product	Estimated Peak Annual U.S. Sales	Regulatory Pathway Note
AVERSA Fentanyl	$80 million to $200 million	Relies primarily on a single Phase 1 Human Abuse Potential study; no Phase 2 or 3 trials required for 505(b)(2) NDA submission.
AVERSA Buprenorphine	Up to $130 million	Second application leveraging the same core technology.

The reduced risk profile for patients and prescribers is a key differentiator. Nutriband Inc. received final meeting minutes from the US FDA following a Type C meeting on September 18, 2025, regarding the Chemistry, Manufacturing, and Controls (CMC) plans for AVERSA Fentanyl. The FDA confirmed the regulatory pathway is a 505(b)(2) NDA, and the company is incorporating feedback as it moves toward an Investigational New Drug (IND) filing to support the required Human Abuse Potential (HAP) clinical study. This streamlined path significantly limits development complexity and time compared to conventional drug development.

Also providing tangible value right now is the contract manufacturing of high-quality, US-made kinesiology tape through the Pocono Pharma subsidiary. This segment generates current revenue and supports the clinical advancement of the AVERSA platform. For the six months ended July 31, 2025, the company reported revenue of $1,289,884, which represented a 50.87% year-over-year increase. This growth is fueled by expanding production and penetration pricing.

The value proposition in the tape segment is market access and quality:

• Expanded output through the Pocono Pharma subsidiary.
• Products rolling out into prominent retail locations nationwide.
• Key retail partners include Target, Walmart, Walgreens, and CVS.

Financially, this segment provided a strong base as of July 31, 2025, with cash reserves standing at $6.9 million, supporting the ongoing development efforts for AVERSA Fentanyl. The company's total assets were valued at $10.17 million, with stockholders' equity at $8.5 million. Furthermore, the AVERSA technology itself is protected by a broad intellectual property portfolio, with patents issued in 46 countries and territories, including the United States and Europe. Finance: draft 13-week cash view by Friday.

Nutriband Inc. (NTRB) - Canvas Business Model: Customer Relationships

You're looking at how Nutriband Inc. manages its different customer groups, which really fall into two distinct camps: the high-stakes pharma development side and the high-volume consumer goods side through Pocono Pharma. The relationship style shifts dramatically between these segments.

High-touch, collaborative relationships with pharmaceutical development partners.

For the AVERSA technology pipeline, the relationship with partners like Kindeva Drug Delivery is deep and collaborative. This is not a simple vendor setup; it's a formalized exclusive product development partnership focused on AVERSA Fentanyl.

• The structure involves shared development costs.
• Nutriband Inc. receives milestone payments in exchange for advancing the technology.
• The lead product, AVERSA Fentanyl, has an estimated peak annual US sales potential of $80 million to $200 million.
• The second application, AVERSA Buprenorphine, is projected to reach peak annual sales of up to $130 million.

This relationship is critical as it directly supports the highlight of 2025: the submission of the AVERSA Fentanyl New Drug Application (NDA).

Transactional, volume-based relationships with large retail brands (Pocono Pharma).

The Pocono Pharma subsidiary operates on a classic business-to-business, volume-driven model, focusing on contract manufacturing of kinesiology tape. The goal here is market penetration through pricing strategy.

Here's a look at the recent performance driving these transactional relationships:

Metric	Value as of Late 2025	Context
Revenue (Six Months Ended July 31, 2025)	$1,289,884	Record six months, up 50.87% YOY.
Revenue (Q1 Ended April 30, 2025)	$667,000USD	Record first quarter, up 63% YOY.
Retail Penetration	Target, Walmart, Walgreens, and CVS	Pocono manufactured products roll out into these prominent retail locations nationwide.

The relationship is cemented by a continued focus on penetration pricing to secure a foothold with these major retailers, making the increasing Pocono revenue stream key to shareholder value.

Investor relations and communication regarding clinical and regulatory milestones.

Communication with the investment community is frequent, tying financial health directly to the drug development timeline. You want to know the cash runway and the next big regulatory step.

• As of July 31, 2025, cash reserves stood at $6.9 million.
• Total assets were valued at $10.17 million, with stockholders' equity at $8.5 million.
• The company presented its progress, including the AVERSA development pathway, at the Emerging Growth Conference on August 20, 2025.
• As of April 30, 2025, the average analyst target price was $13.00, implying an upside of 128.87% from the then-current price of $5.68.

The narrative consistently emphasizes that the NDA submission for AVERSA Fentanyl is the primary focus for 2025, relying on a single Phase 1 Human Abuse Potential study.

Direct-to-consumer marketing for Pocono Pharma's AI Tape brand.

For the Active Intelligence AI Tape brand, the relationship is direct-to-consumer (D2C), initiated back in July 2023. This channel supports the Pocono Pharma revenue base by targeting individual consumers looking for sports recovery products.

The D2C relationship is established through specific online channels:

• Products are available for purchase on Amazon.
• Products are available through the Activeintell.com website.

This consumer channel is manufactured at the Pocono Pharmaceutical facility in North Carolina.

Nutriband Inc. (NTRB) - Canvas Business Model: Channels

You're looking at how Nutriband Inc. gets its value propositions-both the established consumer products and the pipeline pharmaceuticals-to the end-user or partner. It's a dual-track channel strategy, honestly, one for the immediate cash flow and one for the big future payoff.

Direct licensing and commercialization agreements with major pharmaceutical companies

For the AVERSA™ abuse-deterrent technology, the channel to market is heavily reliant on partnerships, not direct sales force build-out, which is smart for a company of this size. Nutriband Inc. is formalizing this through an exclusive product development partnership with Kindeva Drug Delivery for the lead product, AVERSA™ FENTANYL. This arrangement reflects a commitment to shared development costs in exchange for milestone payments, which is a key channel for advancing the drug toward commercialization. Beyond Fentanyl, Nutriband Inc. is advancing AVERSA™ Buprenorphine, which represents an additional estimated revenue stream with projected peak annual sales of up to $130 million. Furthermore, Nutriband Inc. is actively preparing to pursue strategic licensing and distribution agreements internationally to maximize global reach once regulatory hurdles are cleared. The potential for the lead product is substantial, with market analysis estimating AVERSA™ FENTANYL could reach peak annual U.S. sales between $80 million and $200 million.

Here's a quick look at the projected channel value for the AVERSA pipeline:

Product Candidate	Channel Strategy	Estimated Peak Annual U.S. Sales
AVERSA™ FENTANYL	Exclusive Development Partnership (Kindeva) & Future Licensing	$80 million to $200 million
AVERSA™ Buprenorphine	Future Licensing/Partnerships	Up to $130 million

Regulatory submissions to the FDA and other international bodies

The regulatory process is the primary gatekeeper channel for the pharmaceutical segment. Nutriband Inc. has been laser-focused on finalizing its development pathway to FDA approval for AVERSA™ FENTANYL. A critical milestone was the virtual face-to-face meeting held on September 18, 2025, with the US FDA's Division of Anesthesiology, Addiction Medicine, and Pain Medicine (DAAP). The company received final meeting minutes on October 28, 2025, confirming the regulatory pathway as a 505(b)(2) New Drug Application (NDA). This pathway allows Nutriband Inc. to leverage existing fentanyl safety data, meaning no Phase 2 or Phase 3 clinical trials will be required before submission. The immediate next step in this channel is moving forward to an Investigational New Drug (IND) filing in support of a Human Abuse Potential (HAP) clinical study. The intellectual property portfolio supporting this channel is broad, with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.

National retail distribution networks like Target, Walmart, and CVS for Pocono products

The consumer/contract manufacturing channel, run through the Pocono Pharma subsidiary, uses established national retail footprints for immediate revenue generation. Pocono manufactured products continue to roll out into prominent retail locations nationwide. You can find these products on shelves at Target, Walmart, Walgreens, and CVS. This channel is driven by a penetration pricing strategy to gain foothold with large brands. The revenue from this channel is key to supporting the pharmaceutical development. For the first quarter ended April 30, 2025, Nutriband Inc. reported record revenue of $667,000 USD, which was up 63% Year-over-Year (YOY). For the six months ended July 31, 2025, the revenue reached $1,289,884 USD, marking a 50.87% YOY increase. This stream is definitely helping fund the next steps.

• Retail locations confirmed: Target, Walmart, Walgreens, and CVS.
• Q1 2025 Revenue (Pocono): $667,000 USD.
• Six Months Ended July 31, 2025 Revenue (Pocono): $1,289,884 USD.

Company website and investor relations platforms for corporate communication

Corporate communication channels are vital for managing investor expectations, especially given the binary risk/reward of drug development. Nutriband Inc. uses its company website, www.nutriband.com, and investor relations platforms like GlobeNewswire and Nasdaq for official announcements. The company actively communicates milestones, such as the October 28, 2025, announcement detailing the final minutes received from the FDA meeting. To signal internal confidence and manage capital structure, the Board declared a 25% preferred stock dividend, payable August 5, 2025, to shareholders of record on July 25, 2025. These preferred shares are convertible to one common stock share following FDA approval of AVERSA Fentanyl. Financially, as of July 31, 2025, Nutriband Inc.'s cash reserves stood at $6.9 million, with total assets valued at $10.17 million, supporting ongoing development efforts through these communication channels.

The communication channels are backed by a solid, though focused, balance sheet.

• Cash Reserves (as of July 31, 2025): $6.9 million.
• Total Assets (as of July 31, 2025): $10.17 million.
• Preferred Stock Dividend Rate: 25%.

Finance: draft 13-week cash view by Friday.

Nutriband Inc. (NTRB) - Canvas Business Model: Customer Segments

You're looking at the distinct groups Nutriband Inc. (NTRB) serves as of late 2025, which really fall into two main buckets: the high-value pharma licensing side and the steady-revenue contract manufacturing side. It's a dual focus, and the numbers reflect that split effort.

Large pharmaceutical companies seeking abuse-deterrent technology licensing.

This segment is focused on the AVERSA™ platform. The potential here is massive, which is why it drives so much of the valuation discussion. If AVERSA™ Fentanyl gets approved, the estimated peak annual US sales are between $80 million and $200 million. Also, the AVERSA Buprenorphine application has its own projection, potentially reaching up to $130 million in peak annual sales. To protect this, Nutriband Inc. has secured patents for the AVERSA™ technology in 46 countries, including the United States and Europe. The broader abuse deterrent formulations market itself is estimated to hit $39.8 million in 2025. This is where the big licensing deals would land.

Chronic pain patients requiring transdermal opioid therapy.

These patients are the ultimate beneficiaries of the AVERSA™ Fentanyl patch, which aims to be the first and only abuse-deterrent transdermal patch available globally if approved. The technology is designed to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The need is clear, given the potential peak sales figures mentioned above, which directly correlate to the patient population needing effective, yet safer, pain management solutions.

Healthcare providers and pain management specialists.

This group is critical for adoption once AVERSA™ Fentanyl is commercialized. They are the prescribers who need assurance that the delivery system is both effective for pain management and meets the growing regulatory and safety demands around opioid prescribing. The company's progress, such as receiving final meeting minutes from the US FDA on September 18, 2025, for AVERSA™ FENTANYL, directly impacts their confidence in adopting the product.

Major sports and medical brands needing contract tape manufacturing.

This segment is served through the Pocono Pharma subsidiary, providing a current, tangible revenue stream while the AVERSA™ pipeline matures. For the six months ended July 31, 2025, the company reported total revenue of $1,289,884, which includes these contract manufacturing services. This revenue was up 50.87% year-over-year for that six-month period. For context, Q1 2025 revenue was $667,000, up 63% year-over-year. These manufactured products are rolling out into major retail chains, including Target, Walmart, Walgreens, and CVS.

Here's a quick look at the financial snapshot supporting these segments as of mid-2025:

Metric	Value (as of July 31, 2025)	Value (as of Sep 8, 2025)
Trailing 12-Month Revenue	$2.58M	N/A
Cash Reserves	$6.9 million	N/A
Total Assets	$10.17 million	N/A
Market Capitalization	N/A	$69.7M
Stock Price	N/A	$6.26

The company's total assets were listed at $10.17 million as of July 31, 2025, with stockholders' equity at $8.5 million. Honestly, you see the contract business supporting the current operations while the pharma licensing is the future upside.

The customer base is clearly segmented by the revenue source:

• Pharma/Licensing Customers: Target entities for AVERSA™ Fentanyl with $80M-$200M peak sales potential.
• Contract Manufacturing Customers: Brands whose products are stocked in Target, Walmart, Walgreens, and CVS.
• IP Licensees: Entities operating in the 46 countries where AVERSA™ is patented.

Finance: draft 13-week cash view by Friday.

Nutriband Inc. (NTRB) - Canvas Business Model: Cost Structure

You're looking at the cost side of Nutriband Inc. (NTRB) as of late 2025, and it's heavily weighted toward drug development and intellectual property protection. The company's cost structure is clearly dominated by the push to get AVERSA™ Fentanyl approved, which dictates significant spending in specific, high-impact areas.

The most significant cost driver is the Research and Development (R&D) expenses for clinical trials, though Nutriband Inc. has structured this cost to be relatively lean for the lead product. The New Drug Application (NDA) submission for AVERSA™ Fentanyl relies primarily on data from a single Phase 1 Human Abuse Potential study. Importantly, the company has stated that no Phase 2 or Phase 3 clinical trials will be required before submission, which is a major cost mitigation strategy in pharmaceutical development. Still, the overall operating costs result in significant losses, as evidenced by the negative net margin of 398.29% reported in the quarter ending September 9, 2025.

The partnership with Kindeva Drug Delivery directly impacts the cost structure through shared development costs and milestone payments. Nutriband Inc. formalized an exclusive product development partnership where development costs are shared, and the company is committed to making milestone payments to Kindeva Drug Delivery as development progresses for AVERSA™ Fentanyl. This structure shifts some immediate cash outlay for development off the balance sheet but creates contingent future liabilities in the form of those milestone payments.

Manufacturing and operational costs for the Pocono Pharma facility represent another key cost center, although this segment also generates revenue. Pocono Pharma is expanding its kinesiology tape contract manufacturing services. For the six months ended July 31, 2025, this segment contributed to the total revenue of $1,289,884. While specific manufacturing costs aren't itemized, this revenue stream supports the operational overhead of the facility.

General and administrative costs are substantial, reflecting the costs of running a publicly traded pharmaceutical development company. This includes the necessary expense of protecting the AVERSA™ technology globally. Nutriband Inc. maintains its intellectual property through patent maintenance across 46 countries, including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.

Here's a quick look at the financial context surrounding these costs as of late 2025:

Financial Metric	Amount/Detail
Net Loss (Q1 2025, ended April 30, 2025)	$1.39 million
Negative Net Margin (Latest Reported Quarter)	398.29%
Cash Reserves (As of July 31, 2025)	$6.9 million
Pocono Pharma Revenue (Six Months Ended July 31, 2025)	$1,289,884
AVERSA Fentanyl Peak US Sales Potential	$80 million to $200 million

The cost structure is heavily influenced by the R&D path chosen; relying on a single Phase 1 study for the NDA is a deliberate choice to manage the burn rate while pursuing a product with estimated peak US sales between $80 million and $200 million. The company's cash position of $6.9 million as of July 31, 2025, is what supports these ongoing costs.

• Significant R&D cost driver: Single Phase 1 Human Abuse Potential study for NDA.
• IP Cost: Patent maintenance in 46 countries.
• Development Cost Structure: Commitment to shared development costs with Kindeva Drug Delivery.
• Contingent Cost: Obligation for milestone payments to Kindeva Drug Delivery.
• Operational Cost Indicator: Total Assets of $10.17 million as of July 31, 2025.

Finance: draft 13-week cash view by Friday.

Nutriband Inc. (NTRB) - Canvas Business Model: Revenue Streams

You're looking at how Nutriband Inc. currently brings in cash while also sizing up the massive potential from its drug pipeline. Honestly, the revenue picture is split between the here-and-now manufacturing business and the future, high-value licensing/sales from the AVERSA™ drug technology. It's a classic pharma-in-development setup, but the near-term cash flow is important for funding that development.

The established revenue stream comes from contract manufacturing, primarily through the Pocono Pharma subsidiary. This business provides the current financial foundation. For the six months ended July 31, 2025, Nutriband Inc. reported revenue of $1,289,884 from these kinesiology tape contract manufacturing sales, which represented a 50.87% year-over-year increase for that six-month period. This shows solid growth in the existing operations.

The second, and arguably most significant, component of the revenue model involves the proprietary AVERSA™ technology. This is where the big future dollars are expected to land, primarily through licensing deals and eventual product sales.

Here's a quick look at how the current operational revenue stacks up against the projected peak revenues for the AVERSA™ pipeline:

Revenue Stream Type	Product/Activity	Financial Metric	Amount
Current Operations	Contract Manufacturing (Kinesiology Tape)	Revenue (Six Months Ended July 31, 2025)	$1,289,884
Future Pharma Potential	AVERSA Fentanyl (U.S. Peak Annual Sales)	Peak Annual Sales Projection	$80 million to $200 million
Future Pharma Potential	AVERSA Buprenorphine (Peak Annual Sales)	Peak Annual Sales Projection	Up to $130 million

Beyond the direct sales projections for the lead candidates, Nutriband Inc. anticipates revenue from future milestone and royalty payments stemming from the AVERSA™ technology licensing agreements, such as the one formalized with Kindeva Drug Delivery for shared development costs.

To be fair, the near-term financial health supports this pipeline focus. As of July 31, 2025, the company reported cash reserves of $6.9 million, with total assets valued at $10.17 million and stockholders' equity at $8.5 million. This cash position is intended to fund the final development stages, like the planned NDA submission for AVERSA Fentanyl.

The potential revenue streams from the AVERSA pipeline are substantial, suggesting a significant shift in the company's financial profile upon successful commercialization:

• Contract manufacturing sales generated $1.29 million in six months (ended July 31, 2025).
• Future milestone and royalty payments from AVERSA™ technology licensing.
• Potential peak annual U.S. sales of $80 million to $200 million for AVERSA Fentanyl.
• Revenue from other AVERSA pipeline products, like Buprenorphine (projected up to $130 million peak annual sales).

Finance: draft 13-week cash view by Friday.